MedTrace Logo

Post-marketing Safety Surveillance of Compound Kuh-seng Injection: a Registry Study

NCT02239237 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30283

Last updated 2018-10-10

No results posted yet for this study

Summary

This registry aims to monitor the safety of Compound Kuh-seng Injection and to identify the potential risk factors for the adverse drug reactions. Compound Kuh-seng Injection is a kind of natural compound injection extracted from herbs Kuh-seng (Radix Sophorae Flavescentis) and Rhizoma Heterosmilacis Japonicae.

Conditions

  • Safety Surveillance
  • Adverse Drug Events
  • Adverse Drug Reactions
  • Severe Adverse Events
  • Severe Adverse Reactions

Interventions

DRUG

Compound Kuh-seng Injection

Compound Kuh-seng Injection is a kind of natural compound injection extracted from Chinese herbs Kuh-seng (Radix Sophorae Flavescentis) and Rhizoma Heterosmilacis Japonicae. The major bioactive ingredients include oxymatrine，sophocarpidine, matrine, flavonoid etc.

Sponsors & Collaborators

  • Shanxi Zhendong pharmaceutical Co. LTD.

    collaborator UNKNOWN

  • Zhong Wang

    lead OTHER

Principal Investigators

  • Zhong Wang, M.D. · Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences

  • Zhan-Yu Pan, Ph.D. · Tianjin medical university cancer institute & hosptial

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2018-06-30
Completion
2018-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02239237 on ClinicalTrials.gov